Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...

Men with PAH had a larger right heart size and worse survival than women, independent of body size and functional status, a ...

Professor Christopher Denton discusses key aspects of the 2024 British Society for Rheumatology guideline on managing ...